SusanEProckopMD

Pediatric Hematology & Oncology • Boston, MA

Pediatric Bone Marrow Transplant Memorial Sloan-Kettering Cancer Center

Join to view full profile

Dr. Prockop is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Prockop's full profile

Already have an account?

Office
300 Longwood Ave
Boston, MA 02115
Phone+1 617-355-6000

Education & Training

New York Presbyterian Hospital (Cornell Campus)Fellowship, Pediatric Hematology/Oncology, 1997 - 2000
New York Presbyterian Hospital (Columbia Campus)Residency, Pediatrics, 1993 - 1997
Columbia University Vagelos College of Physicians and SurgeonsClass of 1993

Certifications & Licensure

MA State Medical License 2022 - 2026
NY State Medical License 1996 - 2025
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

New York Magazine: Top Doctors Castle Connolly, 2014

Clinical Trials

Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's Tumors Start of enrollment: 2005 Jun 01
Completed
Phase 2
Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine Start of enrollment: 2009 Sep 25
Completed
Phase 2
Patients Treated for Wiskott-Aldrich Syndrome (WAS) Since 1990 Start of enrollment: 2014 Feb 02
Completed
Collection and Generation of Antigen-specific T-lymphocyte Cell Lines From Primary, Third-party, Related, and Unrelated Donors Start of enrollment: 2017 Apr 05
Terminated
Safety and Effectiveness of EBV-specific Cytotoxic T Cells for the Treatment for EBV Lymphomas or Other EBV-associated Malignancies Start of enrollment: 2019 Jun 11
Withdrawn
Phase 2
Join now to see all

Publications & Presentations

PubMed

The Golgi complex governs natural killer cell lytic granule positioning to promote directionality in cytotoxicity.
Luis A Pedroza, Frederique van den Haak, Alexander Frumovitz, Evelyn Hernandez, Everardo Hegewisch-Solloa
Cell Reports. 2025-01-13
1 citations
The role of the conditioning regimen for autologous and ex vivo genetically modified hematopoietic stem cell-based therapies: recommendations from the ISCT stem cell e...
Joseph H Oved, Athena Russell, Amy DeZern, Susan E Prockop, Carmem Bonfim
Cytotherapy. 2025-01-01
1 citations
Allogeneic haematopoietic stem-cell transplantation for children with refractory systemic juvenile idiopathic arthritis and associated lung disease: outcomes from an i...
Michael G Matt, Daniel Drozdov, Elisabeth Bendstrup, Mia Glerup, Ellen-Margrethe Hauge
The Lancet. Rheumatology. 2024-12-20

Abstracts/Posters

Allogeneic CD34-Selected HSCT Following CAR T-Cells Is Associated with Low TRM and Favorable OS in Pediatric/Young Adult Patients with Relapsed/Refractory B-ALL
Susan Prockop, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Let Them Flow: Cell-Based Therapies in Kidney Transplantation
American Society of Nephrology Kidney Week 2019 - Washington, D.C. - 11/8/2019
Long-Term Outcomes of Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) Following Solid Organ (SOT) or Allogeneic Hematop...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Press Mentions

ASBMT: A Model for Medical Self-GovernanceFebruary 26th, 2018